Clinical Trial Update: Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bevacizumab and Abraxane as second-line therapy for metastatic triple-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED